Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715007 | 0.95 | PPARA (0.48) | PPARAKCNH2NOS2MEN1KMT2A | |
| SCHEMBL1715078 | 0.88 | PPARA (0.40) | PPARANOS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2094373 | 0.84 | PPARA (0.57) | PPARAKCNH2PTGS2 | |
| SCHEMBL369102 | 0.83 | PPARA (0.71) | PPARAKCNH2PTGS2CYP3A4MIF | |
| SCHEMBL2094371 | 0.83 | PPARA (0.56) | PPARAKCNH2PTGS2CYP3A4MIF | |
| SCHEMBL8605187 | 0.81 | PPARA (0.57) | PPARAKCNH2NOS2NPC1RAB9A | |
| SCHEMBL1715716 | 0.81 | RAB9A (0.39) | PPARAKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10141470 | 0.79 | PPARA (0.48) | PPARAKCNH2CYP3A4NOS2MEN1 | |
| SCHEMBL8605589 | 0.78 | PPARA (0.57) | PPARAKCNH2PTGS2CYP3A4MIF | |
| SCHEMBL7502255 | 0.77 | PPARA (0.60) | PPARAKCNH2PTGS2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | PPARA 1123/4885KCNH2 4355/4885PTGS2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.